WX-554

WX-554 is an orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MEK, also known as MAP2K or MAPK/ERK kinase). It selectively binds to and inhibits MEK1 and MEK2, thereby preventing the activation of downstream effector proteins such as certain transcription factors. This inhibition disrupts growth factor-mediated cell signaling pathways, leading to reduced tumor cell proliferation. Originally developed by UCB and later by WILEX AG, WX-554 was investigated primarily for the treatment of solid tumors and other cancers. Clinical studies included phase I/II trials in patients with advanced solid tumors to determine safety, pharmacokinetics/pharmacodynamics, optimal biological dose (OBD), and maximum tolerated dose (MTD). The drug demonstrated target inhibition with manageable side effects in early studies but development was discontinued after phase I/II trials[1][3][4][5][7].